Kang Hye Seon, Rhee Chin Kook, Kim Sung Kyoung, Kim Jin Woo, Lee Sang Haak, Yoon Hyung Kyu, Ahn Joong Hyun, Kim Yong Hyun
Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Bucheon St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Int J Chron Obstruct Pulmon Dis. 2016 Oct 3;11:2467-2473. doi: 10.2147/COPD.S116072. eCollection 2016.
We compared the clinical characteristics and treatment outcomes of patients with eosinophilic and neutrophilic COPD exacerbations requiring hospital admission.
This was a retrospective multicenter study performed between January 2010 and December 2014. In all, 1,688 COPD patients admitted via the outpatient clinics or emergency departments of six university hospitals were enrolled. The patients were grouped by complete blood counts: eosinophilic group, >2% peripheral blood eosinophils, and neutrophilic group, >65% peripheral blood neutrophils or >11,000 leukocytes/mL. The patients with radiographic evidence of pneumonia at the time of admission, those with lung cancer, those admitted for treatment of other medical problems, and those who chronically used steroids were excluded.
A total of 605 patients hospitalized with COPD exacerbations (177 eosinophilic and 380 neutrophilic) were included. Pulmonary functions, including the forced expiratory volume in 1 second and forced vital capacity, were better in patients with eosinophilic exacerbations. Treatment outcomes, including the rate of admission to the intensive care unit and mortality, were poorer in patients with neutrophilic exacerbations (4.5% vs 12.4%, =0.004; 1.1% vs 4.5%, =0.043, respectively). Congestive heart failure (odds ratio [OR] =3.40, 95% confidence interval [CI]: 1.28-9.01) and neutrophilic exacerbation (OR = 2.81, 95% CI: 1.21-6.52) were independent risk factors for intensive care unit admission.
COPD patients with neutrophilic exacerbations experienced worse clinical outcomes than did those with eosinophilic exacerbations. The peripheral blood eosinophil count may be a useful predictor of clinical progress during hospitalization of COPD patients with acute exacerbations.
我们比较了因慢性阻塞性肺疾病(COPD)急性加重需住院治疗的嗜酸性粒细胞性和中性粒细胞性COPD患者的临床特征及治疗结果。
这是一项在2010年1月至2014年12月期间进行的回顾性多中心研究。总共纳入了1688例通过6所大学医院门诊或急诊科收治的COPD患者。根据全血细胞计数将患者分组:嗜酸性粒细胞组,外周血嗜酸性粒细胞>2%;中性粒细胞组,外周血中性粒细胞>65%或白细胞>11,000/毫升。排除入院时存在肺炎影像学证据的患者、肺癌患者、因其他医疗问题入院治疗的患者以及长期使用类固醇的患者。
共纳入605例因COPD急性加重住院的患者(177例嗜酸性粒细胞性和380例中性粒细胞性)。嗜酸性粒细胞性急性加重患者的肺功能,包括1秒用力呼气容积和用力肺活量,更好。中性粒细胞性急性加重患者的治疗结果,包括重症监护病房入住率和死亡率,更差(分别为4.5%对12.4%,P = 0.004;1.1%对4.5%,P = 0.043)。充血性心力衰竭(比值比[OR]=3.40,95%置信区间[CI]:1.28 - 9.01)和中性粒细胞性急性加重(OR = 2.81,95% CI:1.21 - 6.52)是重症监护病房入住的独立危险因素。
中性粒细胞性急性加重的COPD患者的临床结果比嗜酸性粒细胞性急性加重的患者更差。外周血嗜酸性粒细胞计数可能是COPD急性加重患者住院期间临床进展的有用预测指标。